213024-76-1

Basic information

• Product Name: 6H-DIBENZ[B,D]AZEPIN-6-ONE, 7-AMINO-5,7-DIHYDRO-5-METHYL-
• Synonyms: 6H-DIBENZ[B,D]AZEPIN-6-ONE, 7-AMINO-5,7-DIHYDRO-5-METHYL-;7-AMino-5-Methyl-5H-dibenzo[b,d]azepin-6(7H)-one;7-AMino-5-Methyl-5H,7H-dibenzo[b,d]azepin-6-one;7-amino-5-methyl-5,7-dihydro-6H-dibenzo[b,d]azepin-6-one
• CAS NO: 213024-76-1
• Molecular Formula: C₁₅H₁₄N₂O
• Molecular Weight: 238.289
• Mol File: 213024-76-1.mol

Chemical Properties

• Boiling Point: 506.67°C at 760 mmHg
• Flash Point: 260.225°C
• Appearance: /
• Density: 1.198g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.625
• CAS DataBase Reference: 6H-DIBENZ[B,D]AZEPIN-6-ONE, 7-AMINO-5,7-DIHYDRO-5-METHYL-(CAS DataBase Reference)
• NIST Chemistry Reference: 6H-DIBENZ[B,D]AZEPIN-6-ONE, 7-AMINO-5,7-DIHYDRO-5-METHYL-(213024-76-1)
• EPA Substance Registry System: 6H-DIBENZ[B,D]AZEPIN-6-ONE, 7-AMINO-5,7-DIHYDRO-5-METHYL-(213024-76-1)

Safety Data

• Hazardous Substances Data: 213024-76-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6H-Dibenz[b,d]azepin-6-one, 7-amino-5,7-dihydro-5-methylis utilized as an active pharmaceutical ingredient for its antipsychotic, antihistaminic, and analgesic properties. It aids in the development of medications targeting psychiatric and neurological disorders.
Used in Research and Development:
As a research chemical, 6H-Dibenz[b,d]azepin-6-one, 7-amino-5,7-dihydro-5-methylplays a crucial role in the discovery and formulation of new drugs for the treatment of various conditions, including psychiatric and neurological disorders.
Used in Anti-inflammatory Applications:
6H-Dibenz[b,d]azepin-6-one, 7-amino-5,7-dihydro-5-methylis studied for its potential anti-inflammatory properties, which could be beneficial in the treatment of inflammatory conditions and diseases.
Used in Antitumor Applications:
6H-Dibenz[b,d]azepin-6-one, 7-amino-5,7-dihydro-5-methylis also being investigated for its possible antitumor activities, indicating its potential use in cancer research and therapeutic development.
Overall, 6H-Dibenz[b,d]azepin-6-one, 7-amino-5,7-dihydro-5-methylis a versatile chemical with a broad spectrum of applications in medicine and pharmaceuticals, offering promising avenues for therapeutic advancements.

InChI:InChI=1/C15H14N2O/c1-17-13-9-5-4-7-11(13)10-6-2-3-8-12(10)14(16)15(17)18/h2-9,14H,16H2,1H3

Upstream product

• 209984-31-6 7-methyl-5-oximo-5,7-dihydro-6H-dibenz[b,d]azepin-6-one 
• 20011-90-9 5H,7H-dibenzo[b,d]azepin-6-one 
• 40400-15-5 2-(2-iodophenyl)acetonitrile 
• 615-36-1 2-bromoaniline 
• 325141-76-2 2-{2'-amino-[1,1'-biphenyl]-2-yl}acetonitrile 
• 209984-30-5 N-methyl-5H-dibenzo[b,d]azepin-6(7H)-one 
• 683277-81-8 (2'-azido-biphenyl-2-yl)-acetonitrile 
• 683277-82-9 (2'-azido-biphenyl-2-yl)-acetic acid 
• 683277-83-0 (2'-azido-biphenyl-2-yl)-acetic acid pentafluorophenyl ester 
• 1243328-12-2 C₂₉H₂₆N₂O 
• 90-41-5 2-phenylaniline 
• 14925-09-8 2-(N-methylamino)-1,1'-biphenyl 
• 955879-95-5 N-([1,1'-biphenyl]-2-yl)-2-chloro-N-methylacetamide 

Downstream Products

• 209994-99-0 7-(L-alaninyl)-amino-5-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one 
• 209984-55-4 (S,S)-7-amino-5-methyl-5H-dibenzo[b,d]azepin-6(7H)-one hydrochloride 
• 959977-20-9 C₂₃H₂₀N₂O₃ 
• 959977-21-0 C₂₃H₂₀N₂O₃ 
• 209984-33-8 (S)-5-(N-Boc-L-alaninyl)amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one 
• 209984-34-9 (R)-5-(N-Boc-L-alaninyl)amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one 
• 209993-15-7 7-{N'-(3,5-difluorophenylacetyl)-4-ethylnorleucinyl}amino-5-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one 

Relevant articles and documents

New flurbiprofen derivatives: Synthesis, membrane affinity and evaluation of in vitro effect on β-amyloid levels

Alzheimer′s disease (AD) is characterized by irreversible and progressive loss of memory and cognition and profound neuronal loss. Current therapeutic strategies for the treatment of AD have been directed to a variety of targets with the aim of reversing or preventing the disease but, unfortunately, the available treatments often produce no significant clinical benefits. During the last decades compounds that inhibit or modulate γ-secretase, reducing β amyloid (Aβ) levels, have been considered as potential therapeutics for AD. Among these the (R)-enantiomer of flurbiprofen (FLU) seems to be very promising, but it shows low brain penetration. In this study, in order to improve the properties of FLU against Alzheimer′s pathogenesis we synthesized some novel FLU lipophilic analogues. Lipophilicity of the new molecules has been characterized in terms of clogP, log KC18/W and log K IAM/W values. Permeability has been determined in both gastrointestinal PAMPA (PAMPA-GI) at different pH values and in brain blood barrier PAMPA (PAMPA-BBB) models. They were also tested for their ability to inhibit in vitro γ-secretase activity using rat CTXTNA2 astrocytes. Interestingly, the investigated molecules demonstrated to reduce Aβ 42 levels without affecting the amyloid precursor protein APP level in a clear concentrations-dependent manner.

Synthesis of dibenzazepinones by palladium-catalyzed intramolecular arylation of o -(2′-Bromophenyl)anilide enolates

A new approach for the convenient synthesis of dibenzazepinones is reported. The key step is the formation of the seven-membered ring through palladium-catalyzed intramolecular arylation of an anilide enolate. T'e reactions were completed in 10 min at 100 °C with moderate to excellent yields. Aminodibenzazepinone 1, the core structure in the γ-secretase inhibitor LY411575, can be prepared in five steps from 2-bromophenylboronic acid and 2-iodoaniline in 60% overall yield. The synthesis reported here compares favorably with presently available approaches to this interesting ring system.

Synthesis and axial chirality of an enantiopure aminodibenzazepinone

A route for the synthesis of (S,S)-7-amino-5-methyl-5H-dibenzo[b,d]azepin-6(7H)-one hydrochloride is disclosed. The synthesis includes a Friedel-Crafts alkylation to form the seven-membered ring and a highly efficient classical resolution. Additional stud

A multigram chemical synthesis of the γ-secretase inhibitor LY411575 and its diastereoisomers

An improved chemical synthesis of N-2((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-l-alaninamide (LY411,575, 9a), a known γ-secretase inhibitor, is described. The key synthetic steps, which

Highly efficient synthesis of medium-sized lactams via intramolecular Staudinger-aza-Wittig reaction of ω-azido pentafluorophenyl ester: Synthesis and biological evaluation of LY411575 analogues

A highly efficient method for the synthesis of medium-sized lactams based on intramolecular Staudinger-aza-Wittig reaction of ω-azido pentafluorophenyl ester has been developed. A variety of 7-10 membered lactams were synthesized in excellent yields. Appl

Substituted lactams as inhibitors of A beta protein production

This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.